Beyond second-line therapy in patients with metastatic colorectal cancer: a systematic review von Arnold, D., Prager, G.W., Quintela, A., Stein, A., Moreno Vera, S., Mounedji, N., Taieb, J.

Volltext

Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory von Sartore-Bianchi, A., Loupakis, F., Argilés, G., Prager, G.W.

Volltext

CD98hc (SLC3A2), a novel marker in renal cell cancer von Prager, G. W., Poettler, M., Schmidinger, M., Mazal, P. R., Susani, M., Zielinski, C. C., Haitel, A.

Volltext

FOLFOXIRI plus bevacizumab as standard of care for first-line treatment in patients with advanced colon cancer von Cervantes, A., Prager, G.W.

Volltext

Clinically meaningful outcomes in refractory metastatic colorectal cancer: a decade of defining and raising the bar von Fakih, M., Prager, G.W., Tabernero, J., Amellal, N., Calleja, E., Taieb, J.

Volltext

Applied Precision Cancer Medicine in Neuro-Oncology von Taghizadeh, H., Müllauer, L., Furtner, J., Hainfellner, J. A., Marosi, C., Preusser, M., Prager, G. W.

Volltext

How we treat esophageal squamous cell carcinoma von Puhr, H.C., Prager, G.W., Ilhan-Mutlu, A.

Volltext

Applied precision cancer medicine in metastatic biliary tract cancer von Taghizadeh, H., Müllauer, L., Mader, R., Prager, G. W.

Volltext

Prognosticators of survival in patients with metastatic pancreatic cancer and ascites von Berger, Julia M., Alany, Ashly, Berchtold, Luzia, Puhr, Mag. Rainer, Friedrich, Alexander, Scheiner, Bernhard, Prager, Gerald W., Preusser, Matthias, Berghoff, Anna S., Bergen, Elisabeth S.

Volltext

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SU... von Tabernero, J., Taieb, J., Fakih, M., Prager, G.W., Van Cutsem, E., Ciardiello, F., Mayer, R.J., Amellal, N., Skanji, D., Calleja, E., Yoshino, T.

Volltext

Clinical risk factors for ascites in metastatic pancreatic cancer von Berger, J.M., Alany, A., Puhr, R., Berchtold, L., Friedrich, A., Scheiner, B., Prager, G.W., Berghoff, A.S., Preusser, M., Bergen, E.S.

Volltext

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity von Mavroeidi, I.-A., Burghofer, J., Kalbourtzis, S., Taghizadeh, H., Webersinke, G., Piringer, G., Kasper, S., Schreil, G., Liffers, S.T., Reichinger, A., Kirchweger, P., Heibl, S., Hamacher, R., Schmitt, C.A., Schuler, M., Prager, G.W., Kersting, D., Treckmann, J., Schildhaus, H.-U., Rumpold, H., Siveke, J.T., Doleschal, B.

Volltext

Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients von Rezaie-Majd, Abdolreza, Prager, Gerald W, Bucek, Robert A, Schernthaner, Gerit H, Maca, Thomas, Kress, Hans-Georg, Valent, Peter, Binder, Bernd R, Minar, Erich, Baghestanian, Mehrdad

Volltext

PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis von Unseld, Matthias, Chilla, Anastasia, Pausz, Clemens, Mawas, Rula, Breuss, Johannes, Zielinski, Christoph, Schabbauer, Gernot, Prager, Gerald W.

Volltext

The urokinase receptor (CD87) represents a central mediator of growth factor-induced endothelial cell migration von Poettler, Marina, Unseld, Matthias, Mihaly-Bison, Judit, Uhrin, Pavel, Koban, Florian, Binder, Bernd R., Zielinski, Christoph C., Prager, Gerald W.

Volltext

Impact of KRAS G12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III S... von Tabernero, J, Taieb, J, Fakih, M, Prager, G W, Van Cutsem, E, Ciardiello, F, Mayer, R J, Amellal, N, Skanji, D, Calleja, E, Yoshino, T

Volltext

Bead-Based Isolation of Circulating Tumor DNA from Pancreatic Cancer Patients Enables High Fidelity Next Generation Sequencing von Balendran-Braun, Sukirthini, Kieler, Markus, Liebmann-Reindl, Sandra, Unseld, Matthias, Bianconi, Daniela, W Prager, Gerald, Streubel, Berthold

Volltext

Dabrafenib plus trametinib in patients with BRAF V600E -mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial von Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek

Volltext

Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial von Wen, Patrick Y, Stein, Alexander, van den Bent, Martin, De Greve, Jacques, Wick, Antje, de Vos, Filip Y F L, von Bubnoff, Nikolas, van Linde, Myra E, Lai, Albert, Prager, Gerald W, Campone, Mario, Fasolo, Angelica, Lopez-Martin, Jose A, Kim, Tae Min, Mason, Warren P, Hofheinz, Ralf-Dieter, Blay, Jean-Yves, Cho, Daniel C, Gazzah, Anas, Pouessel, Damien, Yachnin, Jeffrey, Boran, Aislyn, Burgess, Paul, Ilankumaran, Palanichamy, Gasal, Eduard, Subbiah, Vivek

Volltext

Relationship of 4F2hc expression and grade of malignancy in renal cell cancer (RCC) von Pöttler, M., Novotny, R., Haitel, A., Zielinski, C., Prager, G. W.

Volltext